Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar;2(1):24-8.
doi: 10.1007/s11739-007-0005-2. Epub 2007 Mar 31.

Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy

D Ferro  1 , L Loffredo, L Polimeni, F Violi
Affiliations

Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy

D Ferro et al. Intern Emerg Med. 2007 Mar.

Abstract

Introduction: Oral anticoagulants (OAs) are significantly more effective than Aspirin in the prevention of cerebrovascular accidents among patients with atrial fibrillation (AF). Several studies, however, showed OAs to be widely underused in these patients.

Objective: To assess the appropriateness of antithrombotic therapy in an Italian population of AF patients.

Methods: Two hundred and fifty-five consecutive patients affected by nonvalvular AF participated in the study. Data were collected on demographic characteristics, risk factors for stroke, current prophylactic therapy, and perceived or actual risk factors for bleeding. INR levels were measured. Patients were stratified by their risk for stroke (214 at high risk, 21 moderate, 20 low), and their prophylactic therapy was analysed in light of international antithrombotic therapy recommendations. After therapy adjustment, 203 of our patients were followed-up for the occurrence of cerebrovascular events for an average of 27 months.

Results: Upon admission, 35% (n=75) of patients in the high-risk category were either taking no antithrombotic prophylaxis or were being treated with Aspirin. In addition, 38 of 139 patients receiving OAs had an INR<2. Thus, a total of 113 (52.8%) high-risk subjects were not receiving adequate antithrombotic therapy. Of high-risk patients not treated with OAs, 46.7% reported no perceived or actual risk factors for bleeding. The annual incidence of cerebrovascular accidents was 3.8% among 163 high-risk patients assigned to OA treatment, and 4.5% among 39 patients given Aspirin treatment. Relative to expected annual incidence rates, cerebrovascular risk in anticoagulated patients was reduced by about 70%.

Conclusions: Underuse of OAs is still common in Italy, and much of it cannot be explained by the concern for haemorrhage. Support and training in the complex task of anticoagulation management may help to extend this efficacious prophylactic therapy to all patients who may benefit from it.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Antithrombotic prophylaxis in AF patients (%) by risk category
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1136/bmj.325.7371.1022', 'is_inner': False, 'url': 'https://doi.org/10.1136/bmj.325.7371.1022'}, {'type': 'PMC', 'value': 'PMC1124497', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1124497/'}, {'type': 'PubMed', 'value': '12411366', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12411366/'}]}
    2. Lip GYH, Hart RG, Conway DSG (2002) Antithrombotic therapy for atrial fibrillation. BMJ 325:1022–1025 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1378/chest.119.1_suppl.194S', 'is_inner': False, 'url': 'https://doi.org/10.1378/chest.119.1_suppl.194s'}, {'type': 'PubMed', 'value': '11157649', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11157649/'}]}
    2. Albers GW, Dalen JE, Laupacis A et al (2001) Antithrombotic therapy in atrial fibrillation. Chest 119:194S–206S - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0735-1097(01)01587-X', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0735-1097(01)01587-x'}, {'type': 'PubMed', 'value': '11583910', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11583910/'}]}
    2. Fuster V, Ryden LE (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 38:1231–1266 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/archinte.147.9.1561', 'is_inner': False, 'url': 'https://doi.org/10.1001/archinte.147.9.1561'}, {'type': 'PubMed', 'value': '3632164', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/3632164/'}]}
    2. Wolf PA, Abbott RD, Kannel WB (1987) Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 147:1561–1564 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '8018000', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/8018000/'}]}
    2. — (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457 - PubMed